That will change!; ). U.S analysts are less likely to upset the apple cart. Look, FDA utilizes a more subjective approval process that favors big pharma due to potential influence. The U.S. patent office is lagging behind other jurisdictions in granting the combo patent. Care to guess why? Money talks and you don’t mess with the gravy train. Most analysts in the U.S. will start talking when an MAA approval decision is made and likely not before except maybe a few independents. The reasons for this are fairly obvious that have been often discussed on this board over time which I remind you of again now because you and the crew haven’t been taking anything to help improve your memories lately; ). Best wishes.
Per your comment below, "But yet you can't find a SINGLE U.S. BIOTECH ANALYST backing NWBO. "Well respected German Group" Ah, ha, ha."
Per the facts, "Yes,— Dr. George Zavoico, a senior equity analyst and senior vice president at B. Riley FBR, is a biotech analyst who has covered Northwest Biotherapeutics (NWBO). Zavoico has over a decade of experience as a life sciences equity analyst, focusing on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies InvestorsHub.
His background includes prior roles at JonesTrading Institutional Services LLC, MLV & Co., Cantor Fitzgerald, and Westport Capital Markets, as well as extensive experience in the biotech industry before becoming an analyst. He has also been recognized for his top-ranked earnings estimation skills in the biotech sector InvestorsHub.
While the provided sources do not list a current price target or rating for NWBO from Zavoico, his professional profile and past work indicate that he is a relevant biotech analyst who has engaged with the company. If you want the most up-to-date coverage, you can check B. Riley FBR’s research reports or Zavoico’s analyst profile on financial data platforms. Stock Analysis"
Market Data 
Markets 
